Researchers call for CONSORT revision due to inconsistent Pfizer data

02/5/2013 | OutSourcing-Pharma.com

Researchers are seeking changes to journal publishing standards after they found that clinical trials reported by Pfizer for the seizure drug gabapentin didn't match up with internal reports of the drug studies. Professor Kay Dickersin of Johns Hopkins' Center for Clinical Trials said her team's findings indicate a need to revise the CONSORT statement, which provides a list of information that must be included when publishing trials.

View Full Article in:

OutSourcing-Pharma.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Information Officer
Meridian Health Plan
Detroit, MI
Actuary
NTA Life
Addison, TX
Vice President - Government Products
Health Alliance Plan
Detroit, MI